Welcome to our dedicated page for Solid Biosciences SEC filings (Ticker: SLDB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Solid Biosciences's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Solid Biosciences's regulatory disclosures and financial reporting.
Perceptive Advisors LLC, together with related entities and Joseph Edelman, reports beneficial ownership of 12,046,579 shares of Solid Biosciences Inc. common stock, representing 11.2% of the class. This percentage is based on 107,365,171 shares of common stock, including 139,933 shares issuable upon vested options held by Adam Stone.
The holding is primarily through Perceptive Life Sciences Master Fund, Ltd., which directly holds 11,833,539 common shares and 8,912,655 pre-funded warrants exercisable at $0.001 per share, subject to a 9.99% Beneficial Ownership Limitation that currently prevents any warrant exercise. Perceptive Xontogeny Venture Fund, LP directly holds 73,107 shares. Adam Stone holds options for 217,433 shares, of which 139,933 are exercisable within 60 days; the Master Fund is entitled to receive director compensation from his board service via a management fee offset.
Vestal Point Capital, LP and its Chief Investment Officer, Ryan Wilder, report beneficial ownership of Solid Biosciences Inc. common stock through a fund and a managed account they advise. Their position totals 4,833,796 shares of common stock, including shares issuable upon exercise of pre-funded common stock purchase warrants.
The reported holdings represent 4.8% of Solid Biosciences’ common stock, based on 98,449,606 shares outstanding as of May 8, 2026, and assuming exercise of the warrants. Voting and dispositive power over all reported shares is shared, with no sole voting or dispositive power reported. The filers state that the filing should not be construed as an admission of beneficial ownership for all purposes.
Solid Biosciences Inc. filed a prospectus supplement on August 6, 2026 under its universal shelf registration statement on Form S-3 (File No. 333-287325), covering the offer and sale of up to $200.0 million of common stock pursuant to an Amended and Restated Sales Agreement with Jefferies LLC.
This new supplement follows a prior prospectus supplement under a different Form S-3 that permitted up to $85.0 million of common stock sales; as of the new filing, the company has issued and sold shares for aggregate gross proceeds of approximately $85.0 million under that earlier capacity and will no longer use it for additional sales. A legal opinion from Wilmer Cutler Pickering Hale and Dorr LLP regarding the shares is filed as Exhibit 5.1, and offerings will be made only by means of the new prospectus supplement and base prospectus.
Solid Biosciences Inc. is registering an at-the-market offering of up to $200,000,000 of common stock under an amended sales agreement with Jefferies LLC, which will act as sales agent and receive up to 3.0% of the gross sales price as commission. Sales may be made from time to time through The Nasdaq Global Select Market or other permitted methods deemed an at-the-market offering under Rule 415(a)(4). Shares outstanding were 105,125,366 as of June 30, 2026, and an illustrative dilution calculation using a price of $8.73 per share shows net tangible book value per share rising from $3.56 to $4.43, with dilution of $4.30 per share to new investors if the full $200.0 million is sold. The company plans to use any net proceeds for general corporate purposes, including research and development, preclinical and clinical work, potential acquisitions or in-licenses, debt repayment or refinancing, working capital and capital expenditures.
Solid Biosciences Inc. filed a Form S-3 automatic shelf registration statement that allows it to offer, from time to time after effectiveness, a mix of debt securities, common stock, preferred stock, depositary shares, warrants and units. Specific terms and amounts for each issuance will be set in later prospectus supplements.
The company, a gene therapy-focused life sciences business with programs including SGT-003 for Duchenne muscular dystrophy and other rare cardiac and neuromuscular conditions, states that net proceeds from any offerings are expected to be used for general corporate purposes, including R&D, clinical development, strategic transactions, debt repayment, working capital and capital expenditures.
The filing also details the general terms of potential senior and subordinated debt, capital stock (including “blank check” preferred stock), depositary shares, warrants, and units, as well as registration rights held by certain investors and anti-takeover provisions under Delaware law and the company’s governing documents.
Solid Biosciences Inc. reported a larger net loss as it advanced its neuromuscular and cardiac gene therapy programs in the quarter ended June 30, 2026. Net loss was $54.8 million for the quarter and $111.5 million for the first half, primarily reflecting higher research and development spending.
Research and development expenses rose to $44.3 million in the quarter and $90.4 million year-to-date, driven by SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich’s ataxia, and SGT-501 for CPVT. General and administrative expenses were $13.1 million for the quarter and $24.3 million for six months.
Cash, cash equivalents and available-for-sale securities totaled $377.7 million as of June 30, 2026, supported by a March 2026 private placement and at-the-market stock sales. The company states it believes this liquidity will fund operating and capital needs into mid-2028.
FMR LLC and Abigail P. Johnson report beneficial ownership of Solid Biosciences Inc. common stock on a Schedule 13G. As of June 30, 2026, they beneficially owned 6,875,956.68 shares of common stock, representing 7.0% of the class.
FMR LLC reports sole voting power over 6,875,423 shares and sole dispositive power over 6,875,956.68 shares, with no shared voting or dispositive power. Abigail P. Johnson reports sole dispositive power over 6,875,956.68 shares and no voting power, reflecting her control position over FMR entities.
The filing notes that one or more other persons have rights to receive dividends or sale proceeds from these shares, but no single such person has an interest exceeding five percent of Solid Biosciences’ outstanding common stock. The securities were acquired and are reported through subsidiaries identified in an attached Exhibit 99.
BlackRock, Inc. reports beneficial ownership of common stock of Solid Biosciences Inc. on a Schedule 13G filing. BlackRock reports beneficial ownership of 6,419,730 shares of Solid Biosciences common stock, representing 6.5% of the outstanding class.
BlackRock has sole voting power over 6,328,941 shares and sole dispositive power over 6,419,730 shares, with no shared voting or dispositive power. Various underlying clients and investors have rights to dividends and sale proceeds, but no single underlying person holds more than five percent of the total outstanding common shares.
Solid Biosciences Inc. director Ian F. Smith increased his equity stake through equity compensation vesting. On July 2, 2026, he exercised restricted stock units to acquire 3,440 shares of Common Stock at a price of $0.00 per share, reflecting a conversion of vested awards rather than an open-market purchase.
The filing shows his direct holdings rose to 138,145 shares of Common Stock after the transaction, and he also holds 6,880 Restricted Stock Units. Footnotes state that restricted stock units convert to common stock on a one-for-one basis and were granted on January 2, 2026, vesting in equal quarterly installments over 12 months.
Solid Biosciences Inc. received an initial ownership report on Form 3 from RA Capital–affiliated entities as ten percent owners. The filing lists indirect holdings of 28,569, 109,661, and 11,897,896 shares of Common Stock held through investment vehicles managed by RA Capital Management, L.P.
The report also shows 8,178,412 Pre-Funded Warrants, each exercisable into one share of Common Stock at an exercise price of $0.001 per share. These warrants are exercisable immediately but subject to a 9.99% beneficial ownership limit that caps how many shares the Fund may hold after exercise.